全文获取类型
收费全文 | 8959篇 |
免费 | 774篇 |
国内免费 | 21篇 |
专业分类
耳鼻咽喉 | 23篇 |
儿科学 | 410篇 |
妇产科学 | 177篇 |
基础医学 | 1417篇 |
口腔科学 | 324篇 |
临床医学 | 966篇 |
内科学 | 1588篇 |
皮肤病学 | 154篇 |
神经病学 | 1059篇 |
特种医学 | 233篇 |
外科学 | 994篇 |
综合类 | 196篇 |
一般理论 | 10篇 |
预防医学 | 779篇 |
眼科学 | 112篇 |
药学 | 708篇 |
中国医学 | 30篇 |
肿瘤学 | 574篇 |
出版年
2021年 | 134篇 |
2020年 | 96篇 |
2019年 | 141篇 |
2018年 | 148篇 |
2017年 | 117篇 |
2016年 | 131篇 |
2015年 | 130篇 |
2014年 | 186篇 |
2013年 | 287篇 |
2012年 | 432篇 |
2011年 | 399篇 |
2010年 | 266篇 |
2009年 | 201篇 |
2008年 | 413篇 |
2007年 | 375篇 |
2006年 | 373篇 |
2005年 | 368篇 |
2004年 | 337篇 |
2003年 | 353篇 |
2002年 | 320篇 |
2001年 | 284篇 |
2000年 | 280篇 |
1999年 | 234篇 |
1998年 | 111篇 |
1997年 | 92篇 |
1996年 | 72篇 |
1995年 | 91篇 |
1994年 | 71篇 |
1993年 | 70篇 |
1992年 | 180篇 |
1991年 | 215篇 |
1990年 | 157篇 |
1989年 | 199篇 |
1988年 | 214篇 |
1987年 | 250篇 |
1986年 | 199篇 |
1985年 | 234篇 |
1984年 | 139篇 |
1983年 | 94篇 |
1982年 | 75篇 |
1981年 | 78篇 |
1980年 | 68篇 |
1979年 | 106篇 |
1978年 | 107篇 |
1977年 | 91篇 |
1976年 | 64篇 |
1975年 | 75篇 |
1974年 | 77篇 |
1973年 | 72篇 |
1972年 | 72篇 |
排序方式: 共有9754条查询结果,搜索用时 15 毫秒
991.
Chang ET Lee VS Canchola AJ Clarke CA Purdie DM Reynolds P Anton-Culver H Bernstein L Deapen D Peel D Pinder R Ross RK Stram DO West DW Wright W Ziogas A Horn-Ross PL 《American journal of epidemiology》2007,165(7):802-813
Dietary phytochemical compounds, including isoflavones and isothiocyanates, may inhibit cancer development but have not yet been examined in prospective epidemiologic studies of ovarian cancer. The authors have investigated the association between consumption of these and other nutrients and ovarian cancer risk in a prospective cohort study. Among 97,275 eligible women in the California Teachers Study cohort who completed the baseline dietary assessment in 1995-1996, 280 women developed invasive or borderline ovarian cancer by December 31, 2003. Multivariable Cox proportional hazards regression, with age as the timescale, was used to estimate relative risks and 95% confidence intervals; all statistical tests were two sided. Intake of isoflavones was associated with lower risk of ovarian cancer. Compared with the risk for women who consumed less than 1 mg of total isoflavones per day, the relative risk of ovarian cancer associated with consumption of more than 3 mg/day was 0.56 (95% confidence interval: 0.33, 0.96). Intake of isothiocyanates or foods high in isothiocyanates was not associated with ovarian cancer risk, nor was intake of macronutrients, antioxidant vitamins, or other micronutrients. Although dietary consumption of isoflavones may be associated with decreased ovarian cancer risk, most dietary factors are unlikely to play a major role in ovarian cancer development. 相似文献
992.
Scotland continues to report higher rates of infection with Escherichia coli O157 than elsewhere in the UK. Infection with E. coli O157 usually manifests as acute, afebrile, painful, bloody diarrhoea and is the commonest cause of Haemolytic Uraemic Syndrome (HUS), an important cause of childhood renal failure. In 1996 an outbreak of E. coli O157 infection in Central Scotland, resulted in over 500 cases and 17 deaths. Ten years on, high-profile outbreaks of E. coli O157 infection in Scotland still result in cases of HUS and fatalities. We sought to identify outcomes and describe pre-hospital clinical management strategies using prospective, national surveillance of paediatric HUS cases, from 2003 to 2006 inclusive. We recommend that children who present with acute, afebrile, and painful bloody diarrhoea be referred to hospital as early as possible for appropriate clinical management. 相似文献
993.
994.
Leyre Zubiri Rachel P. Rosovsky Meghan J. Mooradian A.J. Piper-Vallillo Justin F. Gainor Ryan J. Sullivan Daniel Marte Genevieve M. Boland Xin Gao Ephraim P. Hochberg David P. Ryan Corey McEwen Minh Mai Tanya Sharova Tara E. Soumerai Aditya Bardia Kerry L. Reynolds 《The oncologist》2021,26(8):e1427-e1433
BackgroundThe coronavirus disease 2019 (COVID‐19) pandemic has significantly impacted health care systems. However, to date, the trend of hospitalizations in the oncology patient population has not been studied, and the frequency of nosocomial spread to patients with cancer is not well understood. The objectives of this study were to evaluate the impact of COVID‐19 on inpatient oncology census and determine the nosocomial rate of COVID‐19 in patients with cancer admitted at a large academic center.Materials and MethodsMedical records of patients with cancer diagnosed with COVID‐19 and admitted were reviewed to evaluate the temporal trends in inpatient oncology census during pre–COVID‐19 (January 2019 to February 2020), COVID‐19 (March to May 2020), and post–COVID‐19 surge (June to August 2020) in the region. In addition, nosocomial infection rates of SARS‐CoV‐2 were reviewed.ResultsOverall, the daily inpatient census was steady in 2019 (median, 103; range, 92–118) and until February 2020 (median, 112; range, 102–114). However, there was a major decline from March to May 2020 (median, 68; range, 57–104), with 45.4% lower admissions during April 2020. As the COVID‐19 surge eased, the daily inpatient census over time returned to the pre–COVID‐19 baseline (median, 103; range, 99–111). One patient (1/231, 0.004%) tested positive for SARS‐CoV‐2 13 days after hospitalization, and it is unclear if it was nosocomial or community spread.ConclusionIn this study, inpatient oncology admissions decreased substantially during the COVID‐19 surge but over time returned to the pre–COVID‐19 baseline. With aggressive infection control measures, the rates of nosocomial transmission were exceedingly low and should provide reassurance to those seeking medical care, including inpatient admissions when medically necessary.Implications for PracticeThe COVID‐19 pandemic has had a major impact on the health care system, and cancer patients are a vulnerable population. This study observes a significant decline in the daily inpatient oncology census from March to May 2020 compared with the same time frame in the previous year and examines the potential reasons for this decline. In addition, nosocomial rates of COVID‐19 were investigated, and rates were found to be very low. These findings suggest that aggressive infection control measures can mitigate the nosocomial infection risk among cancer patients and the inpatient setting is a safe environment, providing reassurance. 相似文献
995.
Isaac A. Klein Shoshana M. Rosenberg Kerry L. Reynolds Leyre Zubiri Rachel Rosovsky Andrew J. Piper-Vallillo Xin Gao Genevieve Boland Aditya Bardia Rachel Gaither Hannah Freeman Gregory J. Kirkner Chanu Rhee Michael Klompas Meghan A. Baker Martha Wadleigh Eric P. Winer Camille N. Kotton Ann H. Partridge 《The oncologist》2021,26(8):685-693
996.
997.
Lounsbury DW Reynolds TC Rapkin BD Robson ME Ostroff J 《Social science & medicine (1982)》2007,64(1):213-222
In psychosocial and health-behavioral research, we often request that research participants provide information on significant individuals in their lives, so-called "third parties". Recently there has been a greater recognition of privacy issues and risks in research pertaining to third parties. Reaction on the part of USA federal regulatory authorities to one study [Amber, D. (2000). Case at vcu bring ethics to forefront. , 14, 1], which attempted to collect survey data about the psychiatric history of respondents' parents, has generated such concern and caution that longstanding practices for the collection of social determinants of health data are being questioned and are at risk of being disallowed by Institutional Review Boards (IRBs). In this paper, we consider third party research rights and risks from the perspective of social and behavioral scientists. Focusing on research about health and quality of life, we first discuss the rationale for research methods that elicit contextual information about family members, friends, co-workers, and other social contacts. Second, we discuss the matter of 'privacy' and its central role in the current third party rights and risks dialogue. Next, we describe ways to effectively manage third-party information, building upon current recommendations by the Office for Human Research Protections (OHRP) and Botkin's [(2001). Protecting the privacy of family members in survey and pedigree research. Journal of the American Medical Association, 285(2), 207-211] treatment of the matter for survey and pedigree research. Lastly, we discuss the implications of applying these data collection and management strategies in social and behavioral research. We assert that these recommendations protect the rights of, and minimize the risks to, third parties without impeding social and behavioral health research. 相似文献
998.
Reynolds LW Hoo RK Brill RJ North J Recker DP Verburg KM 《Journal of pain and symptom management》2003,25(2):133-141
This multicenter, randomized, double-blind, placebo-controlled study evaluated the analgesic efficacy and opioid-sparing effects of valdecoxib, a potent COX-2 specific inhibitor, in patients undergoing knee replacement. Patients received morphine by patient-controlled analgesia (PCA), and valdecoxib 40 mg or 80 mg daily, or placebo, for up to two days. Efficacy was assessed by the cumulative amount of morphine administered over 48 hours, pain intensity and patient's evaluation of medication. Morphine consumption over 48 hours by patients receiving valdecoxib 40 mg or 80 mg daily plus morphine was 83.7% and 75.8% (P < 0.05) of the total amount consumed by patients receiving morphine alone. Patients receiving valdecoxib 40 mg and 80 mg daily experienced significantly lower maximum pain intensity on Day 2 (P < 0.05), and rated their study medication significantly higher than patients receiving morphine alone. Valdecoxib plus morphine was well tolerated. Thus, valdecoxib in combination with morphine provides multi-modal analgesia that reduces pain and opioid use and increases patient satisfaction following knee replacement surgery. 相似文献
999.
The endogenous opioids have been implicated as contributing factors to the cardiovascular dysfunction of shock. Opiate receptor antagonists improve cardiovascular function and long-term survival in laboratory animal models of shock. In this communication, evidence of the therapeutic efficacy of opiate antagonists in canine and primate hemorrhagic shock is presented. The animals were hemorrhaged into a reservoir to lower MAP to 45 mmHg and that pressure was maintained for 1 h at which time the reservoir was clamped and treatment initiated. The "shed blood" was returned at t = 120 min and treatment continued until t = 180 min. Opiate antagonists employed included naloxone, naltrexone and the mixed agonist/antagonist agent, nalbuphine. Both naloxone and naltrexone improved cardiac function at doses of 1 and 2 mg/kg. Animal survival was significantly enhanced in the high dose format. Nalbuphine also improved cardiovascular performance at doses from 1 to 4 mg/kg but at higher doses it depressed cardiac performance. The efficacy of the antagonists is attenuated by acidosis and hypothermia. Opiate antagonists may induce cardiac arrhythmias in combination with beta-adrenergic blocking drugs and the efficacy is reduced in animals that received high dose steroid therapy. Thus the use of opiate antagonists would be contraindicated in patients that received drugs such as propranolol or methylprednisolone. There have been no controlled clinical trials of opiate antagonists in human hemorrhagic shock; these are needed for final clarification. 相似文献
1000.